Dr. Gregory G. EnasVice Chairman
Dr. Greg Enas is a highly seasoned executive with almost 30 years of experience with a Fortune 500 pharmaceutical company. Dr. Enas concluded his career at Eli Lilly and Company as Senior Director of U.S. Regulatory Affairs for Lilly Research Laboratories. Prior to that role where he and his team served as chief regulatory negotiation strategists on behalf of the company, Dr. Enas had directed a global team of over 100 statistical and mathematical scientists supporting the clinical, drug safety, drug discovery and manufacturing areas of the company. Dr. Enas also led the Decision Sciences division which provided advanced analytical support to senior corporate management for investment strategy associated with the annual multi-billion dollar R&D budget. After his career with Lilly, Dr. Enas served as a regulatory affairs consultant to Pharma and biotech companies as senior advisor with FBD Consulting, and founded Innovatov, LLC, to continue working to generate best-in-class regulatory development and product approval strategies.
As Vice Chairman at CHORUS, Dr. Enas leads efforts across for-profit, non-profit, and government enterprises to build, grow, and sustain culture-enabled leadership utilizing innovative data-driven approaches.
Dr. Enas serves on a number of trustee and advisory boards, including The Oaks Academy, The Trinity Forum Academy, The Harrison Center for the Arts, Justice Ventures International, and CHORUS, Inc. He is also actively engaged as a student mentor in public education, an adult educator in various settings, and public square musician and creative.
Dr. Enas received his B.S. in mathematical sciences from Biola University and his Ph.D. in biostatistics from the Medical College in Virginia, Virginia Commonwealth University. In 2010, Dr. Enas received the Pharmaceutical Research & Manufacturers Association Career Achievement Award from the Biostatistics and Data Management Technical Group for significant life-long contributions and innovations to the industry.
Planning is good, delivering on that plan is better, and learning from that mission best enables the enterprise to grow into a more promising future.